Ambispective cohort study of the incidence of the use of atorvastatin with ventilator-associated pneumonia

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017647

Enrollment

Unknown

Registered

2018-08-08

Start date

2018-08-01

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator Associated Pneumonia

Interventions

Group 1:Atorvastatin use

Group 2:Non statin exposure

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients with endotracheal intubation and ventilation; (2) The use of ventilation time is greater than 48 hours

Exclusion criteria

Exclusion criteria: (1) Age less than 18 years; (2) Diagnosis of active pneumonia; (3) Severe hepatic dysfunction:More than three times times the normal limit of ALT; AST three times greater than the normal up limit ; total bilirubin three times more than the normal up limit; (4) Estimated patient survival time is less than 48 hours; (5) All kinds of tumor disease patients; (6) Pregnancy; (7) Receiving immunosuppressive therapy; (8) refusal to sign consent (forward).

Design outcomes

Primary

Measure	Time frame
incidence of ventilator associated pneumonia;	—

Secondary

Measure	Time frame
survival;ventilator free time;free ICU stay;Hospital lenght of stay;CRRT free time;Inflammatory factor level;	—

Countries

China

Contacts

Public ContactDu, Jiang

Shanghai General Hospital

gowindj@163.com+86 18616129392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026